Epsilon Molecular Engineering raises from Saitama Shibusawa MIX Innovation Fund
What's the deal? Epsilon Molecular EngineeringDealroom has a profile for this one. Try Dealroom →, a biotech startup spun out of Saitama University in Japan, has received an investment from the Saitama Shibusawa MIX Innovation Fund. The fund was co-established by Miraidoor, Saitama Prefecture, Japan Finance Corporation, and regional financial institutions. Saitama Resona BankDealroom has a profile for this one. Try Dealroom → and Japan Finance Corporation also participated through co-ordinated financing. The specific funding amount was not disclosed.
Founded in 2016, Epsilon Molecular Engineering has developed a proprietary "cDNA display technology" that produces antibodies without using animals. Its synthetic library approach enables faster, more accurate screening of diverse antibodies — particularly VHH antibodies derived from camelid species, which are gaining attention as next-generation therapeutics.
The company plans to expand into screening conventional IgG monoclonal antibodies as well, targeting applications across pharmaceuticals, in vitro diagnostics, and research reagents.
Why now? Animal-free antibody production is gaining traction globally as the biopharma industry seeks faster, more scalable, and more ethical alternatives to traditional methods. VHH antibodies — smaller and more stable than conventional antibodies — are increasingly seen as a promising frontier in drug development and diagnostics.
What could go wrong? University spinouts in deep tech often face long timelines to commercialisation and regulatory approval. Epsilon Molecular Engineering will need to prove its platform can compete with established antibody discovery firms that have larger pipelines and global reach. The lack of a disclosed funding figure also makes it difficult to assess the scale of resources now available to the company.
The signal: Epsilon Molecular Engineering sits at the "early growth" stage according to Dealroom, yet its investor base — a regional government-backed fund, a public finance corporation, and Saitama Resona Bank acting as an investment fund — reads more like a policy initiative than a traditional venture round. That structure underscores how Japan is increasingly using blended public-private vehicles to de-risk deep-tech bets outside Tokyo, particularly for university spinouts whose commercialisation timelines may be too long for conventional VC appetite.
Read more: PR TIMES
